Watson’s Generic Lidoderm Receives FDA Approval

Watson Pharmaceuticals announced that its subsidiary, Watson Laboratories, has received final approval from the FDA on its ANDA for lidocaine topical patch 5%, the generic equivalent to Endo’s Lidoderm.
The Sacramento Bee